GlassScriptPhysician profile
Tien T Vo
NPI 1891964904
$6,458.49
in general payments reported to CMS, 2019-2025
58 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,106 · 2021: $903 · 2022: $690 · 2023: $770 · 2024: $511 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.36 | 2019-2024 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $572.21 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $456.69 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $417.83 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $401.07 | 2019-2025 | Wegovy, Saxenda |
| Ironwood Pharmaceuticals, INC | $269.69 | 2019-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $268.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $261.20 | 2019-2025 | |
| Abbvie INC. | $229.63 | 2019-2025 | Rinvoq, Humira |
| Abbott Laboratories | $220.56 | 2021-2025 | Freestyle Libre 3 |
| Biotronik INC. | $204.95 | 2023 | Biomonitor |
| Janssen Pharmaceuticals, INC | $202.78 | 2019-2021 | |
| Amgen INC. | $173.59 | 2019-2024 | Repatha, Otezla, Tavneos |
| Amarin Pharma, INC. | $145.34 | 2019-2021 | |
| Lilly USA, LLC | $143.75 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tien Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.